Treatment-related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Riko Ikeda; Yoh Matsuoka; Masaharu Inoue; Ayataka Ishikawa; Kiwamu Akagi; Yukio Kageyama

doi:10.1002/iju5.12679

Treatment-related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

IJU Case Rep. 2023 Dec 8;7(2):115-119. doi: 10.1002/iju5.12679. eCollection 2024 Mar.

Authors

Riko Ikeda¹, Yoh Matsuoka¹, Masaharu Inoue¹, Ayataka Ishikawa², Kiwamu Akagi³, Yukio Kageyama¹

Affiliations

¹ Department of Urology Saitama Cancer Center Saitama Japan.
² Department of Pathology Saitama Cancer Center Saitama Japan.
³ Department of Molecular Diagnosis and Cancer Prevention Saitama Cancer Center Saitama Japan.

Abstract

Introduction: The efficacy of olaparib for treatment-related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment-related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1-year efficacy.

Case presentation: A 75-year-old man initially diagnosed with prostate adenocarcinoma developed treatment-related neuroendocrine prostate cancer after 10-year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation. FoundationOne® detected a BRCA2 gene mutation, and olaparib was initiated after repeating one chemotherapy course using the same chemotherapeutic agents. The patient received olaparib with sustained tumor regression for 1 year without severe side effects.

Conclusion: Olaparib may be the treatment of choice for treatment-related neuroendocrine prostate cancer in patients with BRCA mutations.

Keywords: BRCA2; castration‐resistant; neuroendocrine tumor; poly(ADP‐ribose) polymerase inhibitors; prostate cancer.

Publication types

Case Reports